title: Radionuclide therapy of cancer patients with bone metastases.
abstract: OBJECTIVE
  We report our experience in the use of radionuclides in the treatment of bone metastases in patients with various primary cancers: breast cancer, prostate cancer, lung cancer, etc.
  
  
  METHODS
  Eighty-seven patients (53 women, 34 men) with bone metastases were treated for pain relief with either 32-P (71 patients) or 89-Sr (16 patients). Fifty-three of the patients had breast cancer, 27--rostate cancer, 6--lung cancer and 1--kidney cancer. The patients were examined for side effects when 32-P was administered perorally and 89-Sr injected intravenously. We also studied the changes in the levels of hemoglobin, white blood cells (WBCs) count and platelets count.
  
  
  RESULTS
  We found a significant decrease in the WBC and platelet count in the patients treated with 32-P (U = 2.20, P < 0.05 and U = 4.57, P < 0.001) one month after the therapy. These parameters showed no significant decrease in the group treated with 89-Sr. The pain, which was the rationale to use the radioactive isotopes, was relieved and the patients restored their previous mobility.
  
  
  CONCLUSIONS
  The fact that 32-P alleviated the grave symptom of pain at the relatively weak radiation dose used (2 mCi) is a strong indication that this radiopharmaceutical can be used successfully for such a purpose, although some authors argue against its use in view of the myelosuppresion it causes. This myelosuppression, however, is mild and transient even without treatment and patients could benefit from this adjuvant treatment to manage the pain syndrome. 89-Sr administered intravenously in a dose of 4mCi also relieves pain efficiently but its use is limited by the cost of the quantity needed for 1 patient and for a single dose. The National Health Insurance Fund currently reimburses for a very limited quantity of this substance which makes the cost of the procedure 15 times as expensive as that using radioactive phosphorus.
  
  
  CONCLUSIONS
  Using the radiopharmaceuticals 32-P and 89-Sr provides an additional, easy and efficacious means for palliation of cancer patients with bone metastases, especially those who are refractory to percutaneous irradiation.
authors.affiliation: Department of Radiotherapy and Nuclear Medicine, Medical University, Plovdiv, 15A Vassil Aprilov St., 4002 Plovdiv, Bulgaria.
authors.forename: Marianna P
authors.initials: MP
authors.lastname: Yaneva
authors.forename: Maria
authors.initials: M
authors.lastname: Semerdjieva
authors.forename: Ljudmil R
authors.initials: LR
authors.lastname: Radev
authors.forename: Elena K
authors.initials: EK
authors.lastname: Ivanova
authors.forename: Mihaelina
authors.initials: M
authors.lastname: Geiman
authors.forename: Maria Il
authors.initials: MI
authors.lastname: Vlaikova
authors.forename: Ljubka St
authors.initials: LS
authors.lastname: Mihova
mesh_terms: D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D010146:Pain / Q000532:radiotherapy; D010147:Pain Measurement; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use; D010976:Platelet Count; D011471:Prostatic Neoplasms / Q000473:pathology; D013326:Strontium Radioisotopes / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010761:Phosphorus Radioisotopes; D013326:Strontium Radioisotopes